Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy

Alessandro Antonelli, Mario Rotondi, Poupak Fallahi, Paola Romagnani, Silvia Martina Ferrari, Lucio Barani, Ele Ferrannini, Mario Serio

Research output: Contribution to journalArticle

Abstract

Background: CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment. Objective: To evaluate sCXCL10 in GD. Design: Cross-sectional. Patients: One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16 toxic nodular goitre (TNG) patients and 70 healthy controls (age- and sex-matched). Measurements: We measured sCXCL10 in patients and controls, to relate this parameter to the clinical phenotype. Results: Mean sCXCL10 in GD and AT patients were comparable (122 ± 81 and 133 ± 102 pg/ml) and significantly higher (P <0·01) than in controls or NTMNG patients (73 ± 32 and 76 ± 25 pg/ml, respectively). Hyperthyroid GD had significantly higher sCXCL10 than euthyroid or hypothyroid GD (145 ± 92, 107 ± 56 and 105 ± 46 pg/ml, respectively; P = 0·01). GD patients with untreated hyperthyroidism had higher sCXCL10 than hyperthyroid or euthyroid GD patients under methimazole (MMI) treatment (166 ± 125, 124 ± 41 and 94 ± 35 pg/ml, respectively; P = 0·006). Comparable sCXCL10 levels were observed in newly diagnosed untreated hyperthyroid GD patients with respect to untreated patients with relapse of hyperthyroidism after a previous MMI course (176 ± 125, 155 ± 97 pg/ml, respectively). GD had similar sCXCL10 to AT and higher than TNG patients or controls (all age- and sex-matched) (144 ± 81, 149 ± 114, 101 ± 27 and 86 ± 44 pg/ml, respectively; P = 0·02). Conclusions: sCXCL10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. The reduction in sCXCL10 in treated patients with GD may be related to the immunomodulatory effects of MMI.

Original languageEnglish
Pages (from-to)189-195
Number of pages7
JournalClinical Endocrinology
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Chemokine CXCL10
Methimazole
CXC Chemokines
Graves Disease
Interferons
Serum
Hyperthyroidism
Autoimmune Thyroiditis
Therapeutics
Nodular Goiter
Poisons
Goiter

ASJC Scopus subject areas

  • Endocrinology

Cite this

Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. / Antonelli, Alessandro; Rotondi, Mario; Fallahi, Poupak; Romagnani, Paola; Ferrari, Silvia Martina; Barani, Lucio; Ferrannini, Ele; Serio, Mario.

In: Clinical Endocrinology, Vol. 64, No. 2, 02.2006, p. 189-195.

Research output: Contribution to journalArticle

Antonelli, Alessandro ; Rotondi, Mario ; Fallahi, Poupak ; Romagnani, Paola ; Ferrari, Silvia Martina ; Barani, Lucio ; Ferrannini, Ele ; Serio, Mario. / Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. In: Clinical Endocrinology. 2006 ; Vol. 64, No. 2. pp. 189-195.
@article{26dbebb396244f3c8a53d5b510fdcfea,
title = "Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy",
abstract = "Background: CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment. Objective: To evaluate sCXCL10 in GD. Design: Cross-sectional. Patients: One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16 toxic nodular goitre (TNG) patients and 70 healthy controls (age- and sex-matched). Measurements: We measured sCXCL10 in patients and controls, to relate this parameter to the clinical phenotype. Results: Mean sCXCL10 in GD and AT patients were comparable (122 ± 81 and 133 ± 102 pg/ml) and significantly higher (P <0·01) than in controls or NTMNG patients (73 ± 32 and 76 ± 25 pg/ml, respectively). Hyperthyroid GD had significantly higher sCXCL10 than euthyroid or hypothyroid GD (145 ± 92, 107 ± 56 and 105 ± 46 pg/ml, respectively; P = 0·01). GD patients with untreated hyperthyroidism had higher sCXCL10 than hyperthyroid or euthyroid GD patients under methimazole (MMI) treatment (166 ± 125, 124 ± 41 and 94 ± 35 pg/ml, respectively; P = 0·006). Comparable sCXCL10 levels were observed in newly diagnosed untreated hyperthyroid GD patients with respect to untreated patients with relapse of hyperthyroidism after a previous MMI course (176 ± 125, 155 ± 97 pg/ml, respectively). GD had similar sCXCL10 to AT and higher than TNG patients or controls (all age- and sex-matched) (144 ± 81, 149 ± 114, 101 ± 27 and 86 ± 44 pg/ml, respectively; P = 0·02). Conclusions: sCXCL10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. The reduction in sCXCL10 in treated patients with GD may be related to the immunomodulatory effects of MMI.",
author = "Alessandro Antonelli and Mario Rotondi and Poupak Fallahi and Paola Romagnani and Ferrari, {Silvia Martina} and Lucio Barani and Ele Ferrannini and Mario Serio",
year = "2006",
month = "2",
doi = "10.1111/j.1365-2265.2006.02447.x",
language = "English",
volume = "64",
pages = "189--195",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy

AU - Antonelli, Alessandro

AU - Rotondi, Mario

AU - Fallahi, Poupak

AU - Romagnani, Paola

AU - Ferrari, Silvia Martina

AU - Barani, Lucio

AU - Ferrannini, Ele

AU - Serio, Mario

PY - 2006/2

Y1 - 2006/2

N2 - Background: CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment. Objective: To evaluate sCXCL10 in GD. Design: Cross-sectional. Patients: One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16 toxic nodular goitre (TNG) patients and 70 healthy controls (age- and sex-matched). Measurements: We measured sCXCL10 in patients and controls, to relate this parameter to the clinical phenotype. Results: Mean sCXCL10 in GD and AT patients were comparable (122 ± 81 and 133 ± 102 pg/ml) and significantly higher (P <0·01) than in controls or NTMNG patients (73 ± 32 and 76 ± 25 pg/ml, respectively). Hyperthyroid GD had significantly higher sCXCL10 than euthyroid or hypothyroid GD (145 ± 92, 107 ± 56 and 105 ± 46 pg/ml, respectively; P = 0·01). GD patients with untreated hyperthyroidism had higher sCXCL10 than hyperthyroid or euthyroid GD patients under methimazole (MMI) treatment (166 ± 125, 124 ± 41 and 94 ± 35 pg/ml, respectively; P = 0·006). Comparable sCXCL10 levels were observed in newly diagnosed untreated hyperthyroid GD patients with respect to untreated patients with relapse of hyperthyroidism after a previous MMI course (176 ± 125, 155 ± 97 pg/ml, respectively). GD had similar sCXCL10 to AT and higher than TNG patients or controls (all age- and sex-matched) (144 ± 81, 149 ± 114, 101 ± 27 and 86 ± 44 pg/ml, respectively; P = 0·02). Conclusions: sCXCL10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. The reduction in sCXCL10 in treated patients with GD may be related to the immunomodulatory effects of MMI.

AB - Background: CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment. Objective: To evaluate sCXCL10 in GD. Design: Cross-sectional. Patients: One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16 toxic nodular goitre (TNG) patients and 70 healthy controls (age- and sex-matched). Measurements: We measured sCXCL10 in patients and controls, to relate this parameter to the clinical phenotype. Results: Mean sCXCL10 in GD and AT patients were comparable (122 ± 81 and 133 ± 102 pg/ml) and significantly higher (P <0·01) than in controls or NTMNG patients (73 ± 32 and 76 ± 25 pg/ml, respectively). Hyperthyroid GD had significantly higher sCXCL10 than euthyroid or hypothyroid GD (145 ± 92, 107 ± 56 and 105 ± 46 pg/ml, respectively; P = 0·01). GD patients with untreated hyperthyroidism had higher sCXCL10 than hyperthyroid or euthyroid GD patients under methimazole (MMI) treatment (166 ± 125, 124 ± 41 and 94 ± 35 pg/ml, respectively; P = 0·006). Comparable sCXCL10 levels were observed in newly diagnosed untreated hyperthyroid GD patients with respect to untreated patients with relapse of hyperthyroidism after a previous MMI course (176 ± 125, 155 ± 97 pg/ml, respectively). GD had similar sCXCL10 to AT and higher than TNG patients or controls (all age- and sex-matched) (144 ± 81, 149 ± 114, 101 ± 27 and 86 ± 44 pg/ml, respectively; P = 0·02). Conclusions: sCXCL10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. The reduction in sCXCL10 in treated patients with GD may be related to the immunomodulatory effects of MMI.

UR - http://www.scopus.com/inward/record.url?scp=33645037851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645037851&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2006.02447.x

DO - 10.1111/j.1365-2265.2006.02447.x

M3 - Article

C2 - 16430719

AN - SCOPUS:33645037851

VL - 64

SP - 189

EP - 195

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -